Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
This article was originally published in The Pink Sheet Daily
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.